Baxter and Celgene Shares in Trading Spotlight Ahead of Earnings Reports

Baxter International, Inc. (NYSE:BAX) will unveil its latest earnings on Thursday, January 26, 2012. The average estimate of analysts is for profit of $1.16 per share, a rise of 4.5% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.17. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.16 during the last month. For the year, analysts are projecting net income of $4.30 per share, a rise of 8% from last year.

Last quarter, the company beat estimates by one cent, coming in at profit of $1.09 a share versus the estimate of net income of $1.08 a share. It marked the fourth straight quarter of beating estimates. Analysts are projecting a rise of 2.3% in revenue from the year-earlier quarter to $3.58 billion.

Competitors to Watch: Covidien plc (NYSE:COV), C.R. Bard, Inc. (NYSE:BCR), ICU Medical, Incorporated (NASDAQ:ICUI), Teleflex Incorporated (NYSE:TFX), Hospira, Inc. (NYSE:HSP), CryoLife, Inc. (NYSE:CRY), Becton, Dickinson and Co. (NYSE:BDX), CareFusion Corporation (NYSE:CFN), Haemonetics Corporation (NYSE:HAE), and NxStage Medical, Inc. (NASDAQ:NXTM).

Celgene Corporation (NASDAQ:CELG) will unveil its latest earnings on Thursday, January 26, 2012. The average estimate of analysts is for net income of 95 cents per share, a rise of 46.2% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 85 cents. Between one and three months ago, the average estimate moved up. It has dropped from $1 during the last month. For the year, analysts are projecting profit of $3.33 per share, a rise of 36.5% from last year.

The company is looking to make a streak of three quarters of beating estimates. Last quarter, it beat expectations by reporting net income of 97 cents per share, and the previous quarter, it had profit of 78 cents. Analysts are projecting a rise of 20.6% in revenue from the year-earlier quarter to $1.29 billion.

Competitors to Watch: Novartis AG (NYSE:NVS), SuperGen, Inc. (NASDAQ:SUPG), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Genzyme Corporation (NASDAQ:GENZ), Cell Therapeutics, Inc. (NASDAQ:CTIC), Merck & Co., Inc. (NYSE:MRK), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), and Sanofi-Aventis SA (NYSE:SNY).